Business Context and Reporting Period
DarioHealth Corp., an emerging growth company incorporated in Delaware, filed this Form 8-K on December 18, 2018, reporting events occurring on December 13, 2018. The filing details the entry into a Material Definitive Agreement and the unregistered sale of equity securities.
Key Financial Metrics and Transaction Details
The Company completed a private placement offering with the following terms:
- Gross Proceeds: $3,000,000
- Common Stock Issued: 3,000,000 shares at $1.00 per share
- Warrants Issued: Warrants to purchase up to 3,000,000 shares
- Warrant Exercise Price: $1.25 per share
- Warrant Terms: Exercisable after June 14, 2019; expire December 14, 2021
- Closing Date: December 14, 2018
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics outside of the transaction proceeds.
Material Changes
The primary material change is the increase in equity capital and the issuance of new securities. The Company entered into a Securities Purchase Agreement with five accredited investors. The securities were issued pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, exempting them from registration requirements.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company agreed to file a registration statement covering the resale of the Common Stock and Warrant Shares within ninety days following the closing.
- Transfer Restrictions: The Securities have not been registered and may not be sold in the United States absent registration or an exemption.
- Warrant Features: Investor Warrants include customary anti-dilution protections and may be exercised on a cashless basis if no effective registration statement exists for the resale of Warrant Shares.
- Disclosure Limitation: The filing explicitly states that the Securities Purchase Agreement is not intended as a document for the public to obtain factual information about the Company's current state of affairs.
Investor Verification Checklist
- Verify the filing of the registration statement for resale of securities within the 90-day window post-closing.
- Confirm the impact of the 3,000,000 new shares and potential warrant exercises on existing shareholder dilution.
- Review the Company's subsequent filings for updated cash position and liquidity status following the $3 million raise.
- Check for any amendments to the anti-dilution provisions in the Investor Warrants.